T1 Mapping. Technique and Applications.

Magnetic Resonance Imaging Clinics of North America

Volumn 23, Issue 1, 2015, Pages 25-34

  Fernandes, Juliano Lara ^a   Rochitte, Carlos Eduardo ^b  

^a Cardiovascular Imaging Center Jose Michel Kalaf Research Institute   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiovascular magnetic resonance; Fibrosis; Parametric mapping; T1

Indexed keywords

AORTA VALVE DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL DECISION MAKING; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; EXTRACELLULAR VOLUME MAPPING; FABRY DISEASE; FOLLOW UP; HEART AMYLOIDOSIS; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE PROCESSING; IMAGING AND DISPLAY; INTERMETHOD COMPARISON; LATE GADOLINIUM ENHANCEMENT; MODIFIED LOOK LOCKER INVERSION RECOVERY SEQUENCE; MYOCARDITIS; NATIVE T1 MAPPING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTCONTRAST T1 MAPPING; PROCESS OPTIMIZATION; REVIEW; SATURATION RECOVERY SINGLE SHOT ACQUISITION SEQUENCE; SHORTENED MODIFIED LOOK LOCKER INVERSION RECOVERY SEQUENCE; SIGNAL NOISE RATIO; T1 MAPPING; T1 SEQUENCE; WORKFLOW; ALGORITHM; COMPUTER ASSISTED DIAGNOSIS; HEART DISEASES; IMAGE ENHANCEMENT; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; HEART DISEASES; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84919430543     PISSN: 10649689     EISSN: 15579786     Source Type: Journal    
DOI: 10.1016/j.mric.2014.08.007     Document Type: Review

References (63)

1. Bruder O., Wagner A., Lombardi M., et al. European Cardiovascular Magnetic Resonance (EuroCMR) registry-multi national results from 57 centers in 15 countries. JCardiovasc Magn Reson 2013, 15:9.
2. Turkbey E.B., Nacif M.S., Noureldin R.A., et al. Differentiation of myocardial scar from potential pitfalls and artefacts in delayed enhancement MRI. Br J Radiol 2012, 85(1019):e1145-e1154.
3. Salerno M., Kramer C.M. Advances in parametric mapping with CMR imaging. JACC Cardiovasc Imaging 2013, 6(7):806-822.
4. Kellman P., Hansen M.S. T1-mapping in the heart: accuracy and precision. JCardiovasc Magn Reson 2014, 16(1):2.
5. Look D., Locker D. Time saving in measurement of NMR and EPR relaxation times. Rev Sci Instrum 1970, 41:250-251.
6. Messroghli D.R., Radjenovic A., Kozerke S., et al. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med 2004, 52(1):141-146.
7. Kellman P., Wilson J.R., Xue H., et al. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. JCardiovasc Magn Reson 2012, 14:63.
8. Kellman P., Arai A.E., Xue H. T1 and extracellular volume mapping in the heart: estimation of error maps and the influence of noise on precision. JCardiovasc Magn Reson 2013, 15:56.
9. Piechnik S.K., Ferreira V.M., Dall'Armellina E., et al. Shortened modified Look-Locker inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. JCardiovasc Magn Reson 2010, 12:69.
10. Chow K., Flewitt J.A., Green J.D., et al. Saturation recovery single-shot acquisition (SASHA) for myocardial T mapping. Magn Reson Med 2013, 71(6):2082-2095.
11. Weingartner S., Akcakaya M., Basha T., et al. Combined saturation/inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability. Magn Reson Med 2014, 71(3):1024-1034.
12. Slavin G.S., Stainsby J.A. True T1 mapping with SMART1Map (saturation method using adaptive recovery times for cardiac T1 mapping): a comparison with MOLLI. JCardiovasc Magn Reson 2013, 15(Suppl 1):P3.
13. Moon J.C., Messroghli D.R., Kellman P., et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. JCardiovasc Magn Reson 2013, 15:92.
14. Schelbert E.B., Testa S.M., Meier C.G., et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. JCardiovasc Magn Reson 2011, 13:16.
15. Flett A.S., Hayward M.P., Ashworth M.T., et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010, 122(2):138-144.
16. Ugander M., Oki A.J., Hsu L.Y., et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 2012, 33(10):1268-1278.
17. Kellman P., Wilson J.R., Xue H., et al. Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience. JCardiovasc Magn Reson 2012, 14:64.
18. Mewton N., Liu C.Y., Croisille P., et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. JAm Coll Cardiol 2011, 57(8):891-903.
19. Nigri M., Azevedo C.F., Rochitte C.E., et al. Contrast-enhanced magnetic resonance imaging identifies focal regions of intramyocardial fibrosis in patients with severe aortic valve disease: correlation with quantitative histopathology. Am Heart J 2009, 157(2):361-368.
20. Weidemann F., Herrmann S., Stork S., et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009, 120(7):577-584.
21. Azevedo C.F., Nigri M., Higuchi M.L., et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. JAm Coll Cardiol 2010, 56(4):278-287.
22. Fontana M., White S.K., Banypersad S.M., et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. JCardiovasc Magn Reson 2012, 14:88.
23. White S.K., Sado D.M., Fontana M., et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging 2013, 6(9):955-962.
24. Karamitsos T.D., Piechnik S.K., Banypersad S.M., et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013, 6(4):488-497.
25. Sado D.M., Flett A.S., Banypersad S.M., et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 2012, 98(19):1436-1441.
26. Chin C.W., Semple S., Malley T., et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging 2014, 15(5):556-565.
27. Tanaka M., Fujiwara H., Onodera T., et al. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Heart 1986, 55(6):575-581.
28. Bruder O., Wagner A., Jensen C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 56(11):875-887.
29. O'Hanlon R., Grasso A., Roughton M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 56(11):867-874.
30. Noureldin R.A., Liu S., Nacif M.S., et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. JCardiovasc Magn Reson 2012, 14:17.
31. Shiozaki A.A., Senra T., Arteaga E., et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. JCardiovasc Comput Tomogr 2013, 7(3):173-181.
32. Dass S., Suttie J.J., Piechnik S.K., et al. Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy. Circ Cardiovasc Imaging 2012, 5(6):726-733.
33. Puntmann V.O., Voigt T., Chen Z., et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 2013, 6(4):475-484.
34. Amano Y., Takayama M., Kumita S. Contrast-enhanced myocardial T1-weighted scout (Look-Locker) imaging for the detection of myocardial damages in hypertrophic cardiomyopathy. JMagn Reson Imaging 2009, 30(4):778-784.
35. Moon J.C., Sheppard M., Reed E., et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. JCardiovasc Magn Reson 2006, 8(3):479-482.
36. Moon J.C., Sachdev B., Elkington A.G., et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003, 24(23):2151-2155.
37. Beer M., Weidemann F., Breunig F., et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006, 97(10):1515-1518.
38. Sado D.M., White S.K., Piechnik S.K., et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013, 6(3):392-398.
39. Sheppard M.N., Cane P., Florio R., et al. Adetailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol 2010, 19(5):293-301.
40. McCrohon J.A., Moon J.C., Prasad S.K., et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003, 108(1):54-59.
41. Assomull R.G., Prasad S.K., Lyne J., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. JAm Coll Cardiol 2006, 48(10):1977-1985.
42. Wu K.C., Weiss R.G., Thiemann D.R., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. JAm Coll Cardiol 2008, 51(25):2414-2421.
43. Han Y., Peters D.C., Dokhan B., et al. Shorter difference between myocardium and blood optimal inversion time suggests diffuse fibrosis in dilated cardiomyopathy. JMagn Reson Imaging 2009, 30(5):967-972.
44. Vogelsberg H., Mahrholdt H., Deluigi C.C., et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. JAm Coll Cardiol 2008, 51(10):1022-1030.
45. Maceira A.M., Prasad S.K., Hawkins P.N., et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. JCardiovasc Magn Reson 2008, 10:54.
46. Dungu J.N., Valencia O., Pinney J.H., et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014, 7(2):133-142.
47. Mongeon F.P., Jerosch-Herold M., Coelho-Filho O.R., et al. Quantification of extracellular matrix expansion by CMR in infiltrative heart disease. JACC Cardiovasc Imaging 2012, 5(9):897-907.
48. White J.A., Kim H.W., Shah D., et al. CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. JACC Cardiovasc Imaging 2014, 7(2):143-156.
49. Friedrich M.G., Sechtem U., Schulz-Menger J., et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. JAm Coll Cardiol 2009, 53(17):1475-1487.
50. Mahrholdt H. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 2004, 109(10):1250-1258.
51. Mahrholdt H., Wagner A., Deluigi C.C., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006, 114(15):1581-1590.
52. Grun S., Schumm J., Greulich S., et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. JAm Coll Cardiol 2012, 59(18):1604-1615.
53. Kindermann I., Barth C., Mahfoud F., et al. Update on myocarditis. JAm Coll Cardiol 2012, 59(9):779-792.
54. Ferreira V.M., Piechnik S.K., Dall'Armellina E., et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging 2013, 6(10):1048-1058.
55. Schumm J., Greulich S., Sechtem U., et al. T1 mapping as new diagnostic technique in a case of acute onset of biopsy-proven viral myocarditis. Clin Res Cardiol 2014, 103(5):405-408.
56. Croisille P., Kim H.W., Kim R.J. Controversies in cardiovascular MR imaging: T2-weighted imaging should not be used to delineate the area at risk in ischemic myocardial injury. Radiology 2012, 265(1):12-22.
57. Higgins C.B., Herfkens R., Lipton M.J., et al. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Am J Cardiol 1983, 52(1):184-188.
58. Kim R.J., Fieno D.S., Parrish T.B., et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999, 100(19):1992-2002.
59. Kim R.J., Wu E., Rafael A., et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. NEngl J Med 2000, 343(20):1445-1453.
60. Messroghli D.R., Walters K., Plein S., et al. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med 2007, 58(1):34-40.
61. Chan W., Duffy S.J., White D.A., et al. Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion. JACC Cardiovasc Imaging 2012, 5(9):884-893.
62. Wong T.C., Piehler K., Meier C.G., et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 2012, 126(10):1206-1216.
63. Moon J.C., Treibel T.A., Schelbert E.B. T1 mapping for diffuse myocardial fibrosis: a key biomarker in cardiac disease?. JAm Coll Cardiol 2013, 62(14):1288-1289.